SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. on February 21, 2024, reporting events occurring between February 15 and February 20, 2024. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The filing reports significant departures from the Company's executive and board leadership:
- February 15, 2024: Steve Buhaly resigned as Chief Financial Officer.
- February 19, 2024: Four directors resigned: David Weild IV, Donald E. Foley, Patrick J. Gallagher, and James J. Barry.
- February 20, 2024: Two additional directors resigned: James L. Klein and Frederick D. Hrkac.
The Company explicitly states that none of these resignations resulted from any disagreement regarding the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed beyond the leadership changes. No unusual items were reported.
Investor Verification Checklist
- Verify the appointment of a new Chief Financial Officer to replace Steve Buhaly.
- Confirm the composition of the Board of Directors following the resignation of six members.
- Review subsequent filings for any undisclosed disagreements or strategic shifts related to these departures.
- Check for any impact on the Company's ability to meet financial reporting obligations given the loss of the CFO.